Nontoxic	O
Formulations	O
of	O
Scintillation	O
Nanocrystals	O
for	O
Use	O
as	O
X	B:C0040405
-ray	I:C0040405
Computed	I:C0040405
Tomography	I:C0040405
Contrast	O
Agents	I:C0009924
.	O

Nontoxic	O
Formulations	O
of	O
Scintillation	O
Nanocrystals	O
for	O
Use	O
as	O
X	O
-ray	I:C0040405
Computed	I:C0040405
Tomography	I:C0040405
Contrast	B:C0009924
Agents	I:C0009924
.	O

X	B:C0040405
-	I:C0040405
ray	I:C0040405
computed	I:C0040405
tomography	I:C0040405
(	O
computed	O
tomography	I:C0040405
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	O
,	O
clinical	O
in	O
vivo	I:C1515655
imaging	O
techniques	I:C0079595
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	O
-	I:C0183263
ray	I:C0183263
device	I:C0183263
and	O
contrast	O
enhancement	O
technologies	I:C0969683
.	O

X	O
-	I:C0040405
ray	I:C0040405
computed	I:C0040405
tomography	I:C0040405
(	O
computed	B:C0040405
tomography	I:C0040405
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	O
,	O
clinical	O
in	O
vivo	I:C1515655
imaging	O
techniques	I:C0079595
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	O
-	I:C0183263
ray	I:C0183263
device	I:C0183263
and	O
contrast	O
enhancement	O
technologies	I:C0969683
.	O

X	O
-	I:C0040405
ray	I:C0040405
computed	I:C0040405
tomography	I:C0040405
(	O
computed	O
tomography	I:C0040405
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	B:C2986496
,	O
clinical	O
in	O
vivo	I:C1515655
imaging	O
techniques	I:C0079595
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	O
-	I:C0183263
ray	I:C0183263
device	I:C0183263
and	O
contrast	O
enhancement	O
technologies	I:C0969683
.	O

X	O
-	I:C0040405
ray	I:C0040405
computed	I:C0040405
tomography	I:C0040405
(	O
computed	O
tomography	I:C0040405
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	O
,	O
clinical	O
in	B:C1515655
vivo	I:C1515655
imaging	O
techniques	I:C0079595
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	O
-	I:C0183263
ray	I:C0183263
device	I:C0183263
and	O
contrast	O
enhancement	O
technologies	I:C0969683
.	O

X	O
-	I:C0040405
ray	I:C0040405
computed	I:C0040405
tomography	I:C0040405
(	O
computed	O
tomography	I:C0040405
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	O
,	O
clinical	O
in	O
vivo	I:C1515655
imaging	B:C0079595
techniques	I:C0079595
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	O
-	I:C0183263
ray	I:C0183263
device	I:C0183263
and	O
contrast	O
enhancement	O
technologies	I:C0969683
.	O

X	O
-	I:C0040405
ray	I:C0040405
computed	I:C0040405
tomography	I:C0040405
(	O
computed	O
tomography	I:C0040405
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	O
,	O
clinical	O
in	O
vivo	I:C1515655
imaging	O
techniques	I:C0079595
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	B:C0183263
-	I:C0183263
ray	I:C0183263
device	I:C0183263
and	O
contrast	O
enhancement	O
technologies	I:C0969683
.	O

X	O
-	I:C0040405
ray	I:C0040405
computed	I:C0040405
tomography	I:C0040405
(	O
computed	O
tomography	I:C0040405
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	O
,	O
clinical	O
in	O
vivo	I:C1515655
imaging	O
techniques	I:C0079595
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	O
-	I:C0183263
ray	I:C0183263
device	I:C0183263
and	O
contrast	O
enhancement	B:C0969683
technologies	I:C0969683
.	O

The	O
present	O
study	B:C2603343
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	I:C0077513
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	O
agents	I:C0009924
for	O
X	O
-ray	I:C0043299
,	O
radiation	O
,	O
and	O
CT	O
imaging	I:C0040405
,	O
because	O
of	O
the	O
high	O
X	O
-	I:C0043299
ray	I:C0043299
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	B:C0077513
tungstates	I:C0077513
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	O
agents	I:C0009924
for	O
X	O
-ray	I:C0043299
,	O
radiation	O
,	O
and	O
CT	O
imaging	I:C0040405
,	O
because	O
of	O
the	O
high	O
X	O
-	I:C0043299
ray	I:C0043299
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	I:C0077513
(	O
such	O
as	O
CaWO4	B:C0054486
)	O
are	O
promising	O
contrast	O
agents	I:C0009924
for	O
X	O
-ray	I:C0043299
,	O
radiation	O
,	O
and	O
CT	O
imaging	I:C0040405
,	O
because	O
of	O
the	O
high	O
X	O
-	I:C0043299
ray	I:C0043299
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	I:C0077513
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	B:C0009924
agents	I:C0009924
for	O
X	O
-ray	I:C0043299
,	O
radiation	O
,	O
and	O
CT	O
imaging	I:C0040405
,	O
because	O
of	O
the	O
high	O
X	O
-	I:C0043299
ray	I:C0043299
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	I:C0077513
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	O
agents	I:C0009924
for	O
X	B:C0043299
-ray	I:C0043299
,	O
radiation	O
,	O
and	O
CT	O
imaging	I:C0040405
,	O
because	O
of	O
the	O
high	O
X	O
-	I:C0043299
ray	I:C0043299
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	I:C0077513
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	O
agents	I:C0009924
for	O
X	O
-ray	I:C0043299
,	O
radiation	O
,	O
and	O
CT	B:C0040405
imaging	I:C0040405
,	O
because	O
of	O
the	O
high	O
X	O
-	I:C0043299
ray	I:C0043299
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	I:C0077513
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	O
agents	I:C0009924
for	O
X	O
-ray	I:C0043299
,	O
radiation	O
,	O
and	O
CT	O
imaging	I:C0040405
,	O
because	O
of	O
the	O
high	O
X	B:C0043299
-	I:C0043299
ray	I:C0043299
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	I:C0077513
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	O
agents	I:C0009924
for	O
X	O
-ray	I:C0043299
,	O
radiation	O
,	O
and	O
CT	O
imaging	I:C0040405
,	O
because	O
of	O
the	O
high	O
X	O
-	I:C0043299
ray	I:C0043299
mass	O
attenuation	O
of	O
tungsten	B:C0041383
(	O
W	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	I:C0077513
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	O
agents	I:C0009924
for	O
X	O
-ray	I:C0043299
,	O
radiation	O
,	O
and	O
CT	O
imaging	I:C0040405
,	O
because	O
of	O
the	O
high	O
X	O
-	I:C0043299
ray	I:C0043299
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	B:C0041383
)	O
.	O

We	O
have	O
developed	O
a	O
method	O
of	O
formulation	O
,	O
in	O
which	O
CaWO4	B:C0054486
(	O
CaWO4	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
are	O
encapsulated	O
within	O
a	O
biocompatible	O
poly	O
(	I:C0257395
ethylene	I:C0257395
glycol	I:C0257395
-	I:C0257395
b-	I:C0257395
d	I:C0257395
,	I:C0257395
l-	I:C0257395
lactic	I:C0257395
acid	I:C0257395
)	I:C0257395
(	I:C0257395
PEG	I:C0257395
-	I:C0257395
PLA	I:C0257395
)	I:C0257395
block	I:C0257395
copolymer	I:C0257395
(	I:C0257395
BCP	I:C0257395
)	I:C0257395
capsule	I:C0257395
.	O

We	O
have	O
developed	O
a	O
method	O
of	O
formulation	O
,	O
in	O
which	O
CaWO4	O
(	O
CaWO4	B:C0054486
)	O
nanoparticles	O
(	O
NPs	O
)	O
are	O
encapsulated	O
within	O
a	O
biocompatible	O
poly	O
(	I:C0257395
ethylene	I:C0257395
glycol	I:C0257395
-	I:C0257395
b-	I:C0257395
d	I:C0257395
,	I:C0257395
l-	I:C0257395
lactic	I:C0257395
acid	I:C0257395
)	I:C0257395
(	I:C0257395
PEG	I:C0257395
-	I:C0257395
PLA	I:C0257395
)	I:C0257395
block	I:C0257395
copolymer	I:C0257395
(	I:C0257395
BCP	I:C0257395
)	I:C0257395
capsule	I:C0257395
.	O

We	O
have	O
developed	O
a	O
method	O
of	O
formulation	O
,	O
in	O
which	O
CaWO4	O
(	O
CaWO4	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
are	O
encapsulated	O
within	O
a	O
biocompatible	O
poly	B:C0257395
(	I:C0257395
ethylene	I:C0257395
glycol	I:C0257395
-	I:C0257395
b-	I:C0257395
d	I:C0257395
,	I:C0257395
l-	I:C0257395
lactic	I:C0257395
acid	I:C0257395
)	I:C0257395
(	I:C0257395
PEG	I:C0257395
-	I:C0257395
PLA	I:C0257395
)	I:C0257395
block	I:C0257395
copolymer	I:C0257395
(	I:C0257395
BCP	I:C0257395
)	I:C0257395
capsule	I:C0257395
.	O

We	O
show	O
that	O
these	O
PEG	B:C0257395
-	I:C0257395
PLA	I:C0257395
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
computed	O
tomography	I:C0040405
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	O
-	O
based	O
radiocontrast	O
agents	I:C0009924
(	O
e.g.	O
,	O
Iohexol	O
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	O
or	O
I	O
atoms	O
.	O

We	O
show	O
that	O
these	O
PEG	O
-	I:C0257395
PLA	I:C0257395
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
computed	B:C0040405
tomography	I:C0040405
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	O
-	O
based	O
radiocontrast	O
agents	I:C0009924
(	O
e.g.	O
,	O
Iohexol	O
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	O
or	O
I	O
atoms	O
.	O

We	O
show	O
that	O
these	O
PEG	O
-	I:C0257395
PLA	I:C0257395
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
computed	O
tomography	I:C0040405
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	B:C0021968
-	O
based	O
radiocontrast	O
agents	I:C0009924
(	O
e.g.	O
,	O
Iohexol	O
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	O
or	O
I	O
atoms	O
.	O

We	O
show	O
that	O
these	O
PEG	O
-	I:C0257395
PLA	I:C0257395
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
computed	O
tomography	I:C0040405
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	O
-	O
based	O
radiocontrast	B:C0009924
agents	I:C0009924
(	O
e.g.	O
,	O
Iohexol	O
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	O
or	O
I	O
atoms	O
.	O

We	O
show	O
that	O
these	O
PEG	O
-	I:C0257395
PLA	I:C0257395
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
computed	O
tomography	I:C0040405
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	O
-	O
based	O
radiocontrast	O
agents	I:C0009924
(	O
e.g.	O
,	O
Iohexol	B:C0022005
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	O
or	O
I	O
atoms	O
.	O

We	O
show	O
that	O
these	O
PEG	O
-	I:C0257395
PLA	I:C0257395
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
computed	O
tomography	I:C0040405
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	O
-	O
based	O
radiocontrast	O
agents	I:C0009924
(	O
e.g.	O
,	O
Iohexol	O
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	B:C0041383
or	O
I	O
atoms	O
.	O

We	O
show	O
that	O
these	O
PEG	O
-	I:C0257395
PLA	I:C0257395
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
computed	O
tomography	I:C0040405
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	O
-	O
based	O
radiocontrast	O
agents	I:C0009924
(	O
e.g.	O
,	O
Iohexol	O
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	O
or	O
I	B:C0021968
atoms	O
.	O

We	O
show	O
that	O
these	O
PEG	O
-	I:C0257395
PLA	I:C0257395
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
computed	O
tomography	I:C0040405
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	O
-	O
based	O
radiocontrast	O
agents	I:C0009924
(	O
e.g.	O
,	O
Iohexol	O
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	O
or	O
I	O
atoms	B:C0567415
.	O

PEG	B:C0257395
-	I:C0257395
PLA	I:C0257395
-	O
coated	O
CWO	O
NPs	O
are	O
chemically	O
stable	O
and	O
completely	O
nontoxic	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	B:C0026809
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	O
(	I:C0013125
IV	I:C0013125
)	I:C0013125
administration	I:C0013125
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	O
-	O
coated	O
iron	O
oxide	I:C0060240
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	O
contrast	O
agents	I:C0009924
(	O
MTD	O
in	O
mice	O
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	O
IV	O
)	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	O
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	B:C0013125
(	I:C0013125
IV	I:C0013125
)	I:C0013125
administration	I:C0013125
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	O
-	O
coated	O
iron	O
oxide	I:C0060240
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	O
contrast	O
agents	I:C0009924
(	O
MTD	O
in	O
mice	O
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	O
IV	O
)	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	O
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	O
(	I:C0013125
IV	I:C0013125
)	I:C0013125
administration	I:C0013125
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	B:C0086140
-	O
coated	O
iron	O
oxide	I:C0060240
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	O
contrast	O
agents	I:C0009924
(	O
MTD	O
in	O
mice	O
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	O
IV	O
)	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	O
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	O
(	I:C0013125
IV	I:C0013125
)	I:C0013125
administration	I:C0013125
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	O
-	O
coated	O
iron	B:C0060240
oxide	I:C0060240
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	O
contrast	O
agents	I:C0009924
(	O
MTD	O
in	O
mice	O
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	O
IV	O
)	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	O
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	O
(	I:C0013125
IV	I:C0013125
)	I:C0013125
administration	I:C0013125
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	O
-	O
coated	O
iron	O
oxide	I:C0060240
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	B:C0024485
contrast	O
agents	I:C0009924
(	O
MTD	O
in	O
mice	O
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	O
IV	O
)	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	O
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	O
(	I:C0013125
IV	I:C0013125
)	I:C0013125
administration	I:C0013125
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	O
-	O
coated	O
iron	O
oxide	I:C0060240
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	O
contrast	B:C0009924
agents	I:C0009924
(	O
MTD	O
in	O
mice	O
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	O
IV	O
)	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	O
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	O
(	I:C0013125
IV	I:C0013125
)	I:C0013125
administration	I:C0013125
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	O
-	O
coated	O
iron	O
oxide	I:C0060240
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	O
contrast	O
agents	I:C0009924
(	O
MTD	O
in	O
mice	B:C0026809
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	O
IV	O
)	O
.	O

IV	O
-	O
injected	O
PEG	B:C0257395
-	I:C0257395
PLA	I:C0257395
/	O
CWO	O
NPs	O
caused	O
no	O
histopathologic	O
damage	O
in	O
major	O
excretory	O
organs	I:C0178784
(	O
histopathologic	O
damage	I:C0018787
in	I:C0018787
major	I:C0018787
excretory	I:C0018787
organs	I:C0018787
,	O
liver	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
kidney	O
)	O
.	O

IV	O
-	O
injected	O
PEG	O
-	I:C0257395
PLA	I:C0257395
/	O
CWO	O
NPs	O
caused	O
no	B:C1513916
histopathologic	O
damage	O
in	O
major	O
excretory	O
organs	I:C0178784
(	O
histopathologic	O
damage	I:C0018787
in	I:C0018787
major	I:C0018787
excretory	I:C0018787
organs	I:C0018787
,	O
liver	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
kidney	O
)	O
.	O

IV	O
-	O
injected	O
PEG	O
-	I:C0257395
PLA	I:C0257395
/	O
CWO	O
NPs	O
caused	O
no	O
histopathologic	B:C0677043
damage	O
in	O
major	O
excretory	O
organs	I:C0178784
(	O
histopathologic	O
damage	I:C0018787
in	I:C0018787
major	I:C0018787
excretory	I:C0018787
organs	I:C0018787
,	O
liver	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
kidney	O
)	O
.	O

IV	O
-	O
injected	O
PEG	O
-	I:C0257395
PLA	I:C0257395
/	O
CWO	O
NPs	O
caused	O
no	O
histopathologic	O
damage	O
in	O
major	O
excretory	B:C0178784
organs	I:C0178784
(	O
histopathologic	O
damage	I:C0018787
in	I:C0018787
major	I:C0018787
excretory	I:C0018787
organs	I:C0018787
,	O
liver	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
kidney	O
)	O
.	O

IV	O
-	O
injected	O
PEG	O
-	I:C0257395
PLA	I:C0257395
/	O
CWO	O
NPs	O
caused	O
no	O
histopathologic	O
damage	O
in	O
major	O
excretory	O
organs	I:C0178784
(	O
histopathologic	B:C0018787
damage	I:C0018787
in	I:C0018787
major	I:C0018787
excretory	I:C0018787
organs	I:C0018787
,	O
liver	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
kidney	O
)	O
.	O

IV	O
-	O
injected	O
PEG	O
-	I:C0257395
PLA	I:C0257395
/	O
CWO	O
NPs	O
caused	O
no	O
histopathologic	O
damage	O
in	O
major	O
excretory	O
organs	I:C0178784
(	O
histopathologic	O
damage	I:C0018787
in	I:C0018787
major	I:C0018787
excretory	I:C0018787
organs	I:C0018787
,	O
liver	B:C0023884
,	O
lungs	O
,	O
spleen	O
,	O
and	O
kidney	O
)	O
.	O

IV	O
-	O
injected	O
PEG	O
-	I:C0257395
PLA	I:C0257395
/	O
CWO	O
NPs	O
caused	O
no	O
histopathologic	O
damage	O
in	O
major	O
excretory	O
organs	I:C0178784
(	O
histopathologic	O
damage	I:C0018787
in	I:C0018787
major	I:C0018787
excretory	I:C0018787
organs	I:C0018787
,	O
liver	O
,	O
lungs	B:C0024109
,	O
spleen	O
,	O
and	O
kidney	O
)	O
.	O

IV	O
-	O
injected	O
PEG	O
-	I:C0257395
PLA	I:C0257395
/	O
CWO	O
NPs	O
caused	O
no	O
histopathologic	O
damage	O
in	O
major	O
excretory	O
organs	I:C0178784
(	O
histopathologic	O
damage	I:C0018787
in	I:C0018787
major	I:C0018787
excretory	I:C0018787
organs	I:C0018787
,	O
liver	O
,	O
lungs	O
,	O
spleen	B:C0037993
,	O
and	O
kidney	O
)	O
.	O

IV	O
-	O
injected	O
PEG	O
-	I:C0257395
PLA	I:C0257395
/	O
CWO	O
NPs	O
caused	O
no	O
histopathologic	O
damage	O
in	O
major	O
excretory	O
organs	I:C0178784
(	O
histopathologic	O
damage	I:C0018787
in	I:C0018787
major	I:C0018787
excretory	I:C0018787
organs	I:C0018787
,	O
liver	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
kidney	B:C0022646
)	O
.	O

When	O
an	O
IV	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
was	O
given	O
to	O
mice	B:C0026809
,	O
the	O
blood	O
circulation	I:C0005775
half	O
-	O
life	O
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90	O
%	O
of	O
the	O
NPs	O
were	O
cleared	O
from	O
the	O
mice	O
within	O
24	O
h	O
via	O
the	O
renal	O
and	O
hepatobiliary	O
systems	I:C1711359
.	O

When	O
an	O
IV	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
was	O
given	O
to	O
mice	O
,	O
the	O
blood	B:C0005775
circulation	I:C0005775
half	O
-	O
life	O
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90	O
%	O
of	O
the	O
NPs	O
were	O
cleared	O
from	O
the	O
mice	O
within	O
24	O
h	O
via	O
the	O
renal	O
and	O
hepatobiliary	O
systems	I:C1711359
.	O

When	O
an	O
IV	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
was	O
given	O
to	O
mice	O
,	O
the	O
blood	O
circulation	I:C0005775
half	O
-	O
life	O
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90	O
%	O
of	O
the	O
NPs	O
were	O
cleared	O
from	O
the	O
mice	B:C0026809
within	O
24	O
h	O
via	O
the	O
renal	O
and	O
hepatobiliary	O
systems	I:C1711359
.	O

When	O
an	O
IV	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
was	O
given	O
to	O
mice	O
,	O
the	O
blood	O
circulation	I:C0005775
half	O
-	O
life	O
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90	O
%	O
of	O
the	O
NPs	O
were	O
cleared	O
from	O
the	O
mice	O
within	O
24	O
h	O
via	O
the	O
renal	B:C0022646
and	O
hepatobiliary	O
systems	I:C1711359
.	O

When	O
an	O
IV	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
was	O
given	O
to	O
mice	O
,	O
the	O
blood	O
circulation	I:C0005775
half	O
-	O
life	O
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90	O
%	O
of	O
the	O
NPs	O
were	O
cleared	O
from	O
the	O
mice	O
within	O
24	O
h	O
via	O
the	O
renal	O
and	O
hepatobiliary	B:C1711359
systems	I:C1711359
.	O

When	O
intratumorally	O
administered	O
,	O
PEG	B:C0257395
-	I:C0257395
PLA	I:C0257395
-	O
coated	O
CWO	O
NPs	O
showed	O
complete	O
retention	O
in	O
a	O
tumor	O
-	I:C2986594
bearing	I:C2986594
mouse	I:C2986594
model	I:C2986594
(	O
measurements	O
were	O
made	O
up	O
to	O
1	O
week	O
)	O
.	O

When	O
intratumorally	O
administered	O
,	O
PEG	O
-	I:C0257395
PLA	I:C0257395
-	O
coated	O
CWO	O
NPs	O
showed	O
complete	O
retention	O
in	O
a	O
tumor	B:C2986594
-	I:C2986594
bearing	I:C2986594
mouse	I:C2986594
model	I:C2986594
(	O
measurements	O
were	O
made	O
up	O
to	O
1	O
week	O
)	O
.	O

These	O
results	O
suggest	O
that	O
PEG	B:C0257395
-	I:C0257395
PLA	I:C0257395
-	O
coated	O
CWO	O
NPs	O
are	O
promising	O
materials	O
for	O
use	O
in	O
computed	O
tomography	I:C0040405
contrast	O
.	O

These	O
results	O
suggest	O
that	O
PEG	O
-	I:C0257395
PLA	I:C0257395
-	O
coated	O
CWO	O
NPs	O
are	O
promising	O
materials	O
for	O
use	O
in	O
computed	B:C0040405
tomography	I:C0040405
contrast	O
.	O

